

Kai-Christian Sonntag

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1427408/publications.pdf>

Version: 2024-02-01

38
papers

3,106
citations

257101

24
h-index

360668

35
g-index

38
all docs

38
docs citations

38
times ranked

5250
citing authors

#	ARTICLE	IF	CITATIONS
1	Brain cells derived from Alzheimer's disease patients have multiple specific innate abnormalities in energy metabolism. <i>Molecular Psychiatry</i> , 2021, 26, 5702-5714.	4.1	54
2	Hypothesis and Theory: Characterizing Abnormalities of Energy Metabolism Using a Cellular Platform as a Personalized Medicine Approach for Alzheimer's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 697578.	1.8	4
3	Reactive oxygen species-sensitive nanophotosensitizers of aminophenyl boronic acid pinacol ester conjugated chitosan-glycol-methoxy poly(ethylene glycol) copolymer for photodynamic treatment of cancer. <i>Biomedical Materials (Bristol)</i> , 2020, 15, 055034.	1.7	7
4	The use of laser capture microdissection to identify specific pathways and mechanisms involved in impulsive choice in rats. <i>Heliyon</i> , 2019, 5, e02254.	1.4	3
5	Gene expression profile associated with postnatal development of pyramidal neurons in the human prefrontal cortex implicates ubiquitin ligase E3 in the pathophysiology of schizophrenia onset. <i>Journal of Psychiatric Research</i> , 2018, 102, 110-117.	1.5	10
6	Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. <i>Progress in Neurobiology</i> , 2018, 168, 1-20.	2.8	84
7	Cell Type-Specific Laser Capture Microdissection for Gene Expression Profiling in the Human Brain. <i>Methods in Molecular Biology</i> , 2018, 1723, 203-221.	0.4	5
8	Laser microdissection and gene expression profiling in the human postmortem brain. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 150, 263-272.	1.0	3
9	Late-onset Alzheimer's disease is associated with inherent changes in bioenergetics profiles. <i>Scientific Reports</i> , 2017, 7, 14038.	1.6	96
10	MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons. <i>Molecular Neurobiology</i> , 2016, 53, 95-108.	1.9	48
11	Limited predictability of postmortem human brain tissue quality by RNA integrity numbers. <i>Journal of Neurochemistry</i> , 2016, 138, 53-59.	2.1	36
12	Midbrain dopamine neurons in Parkinson's disease exhibit a dysregulated miRNA and target-gene network. <i>Brain Research</i> , 2015, 1618, 111-121.	1.1	88
13	Differentiation of oligodendrocyte precursors is impaired in the prefrontal cortex in schizophrenia. <i>Schizophrenia Research</i> , 2015, 169, 374-380.	1.1	73
14	Fast and Efficient Neural Conversion of Human Hematopoietic Cells. <i>Stem Cell Reports</i> , 2014, 3, 1118-1131.	2.3	33
15	Poster #M176 MESSENGER RNA AND MICRORNA EXPRESSION PROFILING OF PYRAMIDAL NEURONS, PARVALBUMIN-IMMUNOREACTIVE NEURONS, DOPAMINE NEURONS AND OLIGODENDROCYTES IN SCHIZOPHRENIA AND PARKINSON'S DISEASE. <i>Schizophrenia Research</i> , 2014, 153, S254-S255.	1.1	0
16	Molecular Profiles of Pyramidal Neurons in the Superior Temporal Cortex in Schizophrenia. <i>Journal of Neurogenetics</i> , 2014, 28, 53-69.	0.6	75
17	miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. <i>Neurobiology of Aging</i> , 2014, 35, 1712-1721.	1.5	120
18	Selection Based on FOXA2 Expression Is Not Sufficient to Enrich for Dopamine Neurons From Human Pluripotent Stem Cells. <i>Stem Cells Translational Medicine</i> , 2014, 3, 1032-1042.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Molecular Profiles of Parvalbumin-Immunoreactive Neurons in the Superior Temporal Cortex in Schizophrenia. <i>Journal of Neurogenetics</i> , 2014, 28, 70-85.	0.6	63
20	Converging miRNA functions in diverse brain disorders: A case for miR-124 and miR-126. <i>Experimental Neurology</i> , 2012, 235, 427-435.	2.0	89
21	Detection of Intranasally Delivered Bone Marrow-Derived Mesenchymal Stromal Cells in the Lesioned Mouse Brain: A Cautionary Report. <i>Stem Cells International</i> , 2011, 2011, 1-12.	1.2	17
22	MicroRNAs and deregulated gene expression networks in neurodegeneration. <i>Brain Research</i> , 2010, 1338, 48-57.	1.1	123
23	RNA mechanisms in CNS systems and disorders. <i>Brain Research</i> , 2010, 1338, 1-2.	1.1	6
24	Evidence for Gender-Specific Transcriptional Profiles of Nigral Dopamine Neurons in Parkinson Disease. <i>PLoS ONE</i> , 2010, 5, e8856.	1.1	113
25	Proteasome Activator Enhances Survival of Huntington's Disease Neuronal Model Cells. <i>PLoS ONE</i> , 2007, 2, e238.	1.1	110
26	Enhanced Yield of Neuroepithelial Precursors and Midbrain-Like Dopaminergic Neurons from Human Embryonic Stem Cells Using the Bone Morphogenic Protein Antagonist Noggin. <i>Stem Cells</i> , 2007, 25, 411-418.	1.4	230
27	Markers and Methods for Cell Sorting of Human Embryonic Stem Cell-Derived Neural Cell Populations. <i>Stem Cells</i> , 2007, 25, 2257-2268.	1.4	286
28	Immature and Neurally Differentiated Mouse Embryonic Stem Cells Do Not Express a Functional Fas/Fas Ligand System. <i>Stem Cells</i> , 2007, 25, 2551-2558.	1.4	25
29	Immunological Considerations in CNS Transplants. , 2007, , 305-326.		0
30	Specific MicroRNAs Modulate Embryonic Stem Cell-Derived Neurogenesis. <i>Stem Cells</i> , 2006, 24, 857-864.	1.4	611
31	Tailoring human embryonic stem cells for neurodegenerative disease therapy. <i>Current Opinion in Investigational Drugs</i> , 2006, 7, 614-8.	2.3	9
32	Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. <i>Human Molecular Genetics</i> , 2005, 14, 1709-1725.	1.4	338
33	Stem cells may reshape the prospect of Parkinson's disease therapy. <i>Molecular Brain Research</i> , 2005, 134, 34-51.	2.5	55
34	Implementations of translational medicine. <i>Journal of Translational Medicine</i> , 2005, 3, 33.	1.8	31
35	Human Fas-ligand expression on porcine endothelial cells does not protect against xenogeneic natural killer cytotoxicity*. <i>Xenotransplantation</i> , 2004, 11, 43-52.	1.6	10
36	Generalized brain and skin proteasome inhibition in Huntington's disease. <i>Annals of Neurology</i> , 2004, 56, 319-328.	2.8	164

#	ARTICLE	IF	CITATIONS
37	Tolerance to solid organ transplants through transfer of MHC class II genes. Journal of Clinical Investigation, 2001, 107, 65-71.	3.9	70
38	Nicotinamide riboside and caffeine partially restore diminished NAD availability but not altered energy metabolism in Alzheimer's disease. Aging Cell, 0, , .	3.0	4